

AMENDMENTS

Amendments to the Claims:

The following listing of claims replaces all previous listings or versions thereof:

1.-4. (Canceled)

5. (Currently amended) The method of claim [[12]]6, wherein said retinoid is a material selected from the group consisting of all-trans-retinoic acid (RA); 9-cis retinoic acid (9-cis RA); (E) 4 [2 (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (E)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).

6. (Currently amended) ~~The method of claim 12;~~ A method of treating an individual having a drug-resistant leukemia, comprising the steps of:

- a) administering to said individual a pharmacologically effective dose of a retinoid which up-regulates the expression of CD38 antigen; and
- b) administering to the same individual a pharmacologically effective dose of an immunotoxin directed against CD38 antigen;

wherein said retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.

7. (Canceled)

8. (Currently amended) The method of claim [[12]]6, wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.

9. (Original) The method of claim 8, wherein said toxin is gelonin.

10. (Canceled)

11. (Currently amended) ~~The method of claim 12;~~ A method of treating an individual having a drug-resistant leukemia, comprising the steps of:

- a) administering to said individual a pharmacologically effective dose of a retinoid which up-regulates the expression of CD38 antigen; and
- b) administering to the same individual a pharmacologically effective dose of an immunotoxin directed against CD38 antigen;

wherein said immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.

12. (Canceled)

13. (Currently amended) The method of claim [[12]]6, wherein said drug-resistant leukemia is adriamycin-resistant leukemia.

14. – 15. (Canceled)

16. (New) The method of claim 11, wherein said retinoid is selected from the group consisting of all-trans-retinoic acid (RA); 9-cis retinoic acid (9-cis RA); (E) 4 [2 (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (E)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).

17. (New) The method of claim 11, wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.

18. (New) The method of claim 17, wherein said toxin is gelonin.

19. (New) The method of claim 11, wherein said drug-resistant leukemia is adriamycin-resistant leukemia.